214 related articles for article (PubMed ID: 38231223)
21. The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer.
Han Z; Cheng S; Dai D; Kou Y; Zhang X; Li F; Yin X; Ji J; Zhang Z; Wang X; Zhu N; Zhang Q; Tan Y; Guo X; Shen L; Peng Z
Clin Transl Med; 2023 Jul; 13(7):e1312. PubMed ID: 37381590
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
[TBL] [Abstract][Full Text] [Related]
23. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
[No Abstract] [Full Text] [Related]
24. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
25. Clinical Significance of Molecular Subtypes in Western Advanced Gastric Cancer: A Real-World Multicenter Experience.
Salati M; Ghidini M; Paccagnella M; Reggiani Bonetti L; Bocconi A; Spallanzani A; Gelsomino F; Barbin F; Garrone O; Daniele B; Dominici M; Facciorusso A; Petrillo A
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614254
[TBL] [Abstract][Full Text] [Related]
26. Gastric cancer treatment: recent progress and future perspectives.
Guan WL; He Y; Xu RH
J Hematol Oncol; 2023 May; 16(1):57. PubMed ID: 37245017
[TBL] [Abstract][Full Text] [Related]
27. Influence of Taxanes on Treatment Sequence in Gastric Cancer.
Lorenzen S; Stahl M; Hofheinz RD; Al-Batran SE; Lordick F
Oncol Res Treat; 2020; 43(1-2):42-47. PubMed ID: 31634892
[TBL] [Abstract][Full Text] [Related]
28. Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement Article.
Siebenhüner AR; De Dosso S; Helbling D; Astaras C; Szturz P; Moosmann P; Pederiva S; Winder T; Von Burg P; Borner M
Oncol Res Treat; 2021; 44(9):485-494. PubMed ID: 34350899
[TBL] [Abstract][Full Text] [Related]
29. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
Bouché O; Penault-Llorca F
Bull Cancer; 2010 Dec; 97(12):1429-40. PubMed ID: 21134821
[TBL] [Abstract][Full Text] [Related]
30. Role of microsatellite instability and HER2 positivity in locally advanced esophago-gastric cancer patients treated with peri-operative chemotherapy.
Gervaso L; Bottiglieri L; Meneses-Medina MI; Pellicori S; Biffi R; Fumagalli Romario U; De Pascale S; Sala I; Bagnardi V; Barberis M; Cella CA; Fazio N
Clin Transl Oncol; 2023 Nov; 25(11):3287-3295. PubMed ID: 37084152
[TBL] [Abstract][Full Text] [Related]
31. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Ajani JA; D'Amico TA; Bentrem DJ; Chao J; Cooke D; Corvera C; Das P; Enzinger PC; Enzler T; Fanta P; Farjah F; Gerdes H; Gibson MK; Hochwald S; Hofstetter WL; Ilson DH; Keswani RN; Kim S; Kleinberg LR; Klempner SJ; Lacy J; Ly QP; Matkowskyj KA; McNamara M; Mulcahy MF; Outlaw D; Park H; Perry KA; Pimiento J; Poultsides GA; Reznik S; Roses RE; Strong VE; Su S; Wang HL; Wiesner G; Willett CG; Yakoub D; Yoon H; McMillian N; Pluchino LA
J Natl Compr Canc Netw; 2022 Feb; 20(2):167-192. PubMed ID: 35130500
[TBL] [Abstract][Full Text] [Related]
32. [Unresectable Advanced HER2-Positive Gastric Cancer Leading to a Perforation during Chemotherapy with Trastuzumab plus Paclitaxel].
Ogawa T; Watanabe M; Doita S; Minagi H; Miyake E; Hatono M; Kimura Y; Taniguchi F; Arata T; Katsuda K; Tanakaya K; Aoki H
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1452-1454. PubMed ID: 36733099
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.
Morihiro T; Kuroda S; Kanaya N; Kakiuchi Y; Kubota T; Aoyama K; Tanaka T; Kikuchi S; Nagasaka T; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
Sci Rep; 2019 Mar; 9(1):4633. PubMed ID: 30874607
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy in Gastric Cancer.
Högner A; Moehler M
Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
[TBL] [Abstract][Full Text] [Related]
35. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
Catenacci DVT; Kang YK; Yoon HH; Shim BY; Kim ST; Oh DY; Spira AI; Ulahannan SV; Avery EJ; Boland PM; Chao J; Chung HC; Gardner F; Klempner SJ; Lee KW; Oh SC; Peguero J; Sonbol MB; Shen L; Moehler M; Sun J; Li D; Rosales MK; Park H
ESMO Open; 2022 Oct; 7(5):100563. PubMed ID: 36029651
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma.
Kang C
Target Oncol; 2023 Nov; 18(6):981-989. PubMed ID: 37787931
[TBL] [Abstract][Full Text] [Related]
37. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches.
Ratti M; Lampis A; Hahne JC; Passalacqua R; Valeri N
Cell Mol Life Sci; 2018 Nov; 75(22):4151-4162. PubMed ID: 30173350
[TBL] [Abstract][Full Text] [Related]
38. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
[TBL] [Abstract][Full Text] [Related]
39. Advances in the treatment of gastric cancer.
Ilson DH
Curr Opin Gastroenterol; 2018 Nov; 34(6):465-468. PubMed ID: 30303856
[TBL] [Abstract][Full Text] [Related]
40. Changes in the therapeutic landscape of oesophago-gastric cancers.
Fokter Dovnik N; Smyth EC
Curr Opin Oncol; 2021 Jul; 33(4):362-367. PubMed ID: 33720069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
